Rabinowitsch AI, Maretzky T, Weskamp G, Haxaire C, Tueshaus J, Lichtenthaler SF, Monette S, Blobel CP.  2023.  Analysis of the function of ADAM17 in iRhom2 curly-bare and tylosis with esophageal cancer mutant mice.. J Cell Sci. 136(13)

Bourne CM, Henderson HJ, White E, Morris J, Bah MA, Harewood R, Pierre S, Martins T, Ntereke T, White B et al..  2023.  Black in Cancer: Two Years of Empowering the Next Generation.. Cancer Discov. 13(2):275-277.

Malviya M, Aretz ZEH, Molvi Z, Lee J, Pierre S, Wallisch P, Dao T, Scheinberg DA.  2023.  Challenges and solutions for therapeutic TCR-based agents.. Immunol Rev. 320(1):58-82.

Setton J, Hadi K, Choo Z-N, Kuchin KS, Tian H, Paula ADa Cruz, Rosiene J, Selenica P, Behr J, Yao X et al..  2023.  Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.. Nature. 621(7977):129-137.

Weiss JM, Lumaquin-Yin D, Montal E, Suresh S, Leonhardt CS, White RM.  2022.  Shifting the focus of zebrafish toward a model of the tumor microenvironment.. Elife. 11

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al..  2018.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.. N Engl J Med. 378(8):731-739.

Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM et al..  2018.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.. Nat Immunol. 19(1):76-84.

Janke AM, Seo DHee, Rahmanian V, Conicella AE, Mathews KL, Burke KA, Mittal J, Fawzi NL.  2018.  Lysines in the RNA Polymerase II C-Terminal Domain Contribute to TAF15 Fibril Recruitment.. Biochemistry. 57(17):2549-2563.

Feng M, Marjon KD, Zhu F, Weissman-Tsukamoto R, Levett A, Sullivan K, Kao KS, Markovic M, Bump PA, Jackson HM et al..  2018.  Programmed cell removal by calreticulin in tissue homeostasis and cancer.. Nat Commun. 9(1):3194.

Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AAri, Schietinger A, Scheinberg DA.  2018.  Rejection of immunogenic tumor clones is limited by clonal fraction.. Elife. 7

Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR et al..  2018.  Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.. Nature. 560(7719):499-503.

Asare A, Levorse J, Fuchs E.  2017.  Coupling organelle inheritance with mitosis to balance growth and differentiation.. Science. 355(6324)

Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M et al..  2017.  Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.. Mol Pharm. 14(4):1047-1056.

Cho A, Lau JYC, Geraghty BJ, Cunningham CH, Keshari KR.  2017.  Noninvasive Interrogation of Cancer Metabolism with Hyperpolarized C MRI.. J Nucl Med. 58(8):1201-1206.

J Blander M, Longman RS, Iliev ID, Sonnenberg GF, Artis D.  2017.  Regulation of inflammation by microbiota interactions with the host.. Nat Immunol. 18(8):851-860.

Röhrig F, Vorlová S, Hoffmann H, Wartenberg M, Escorcia FE, Keller S, Tenspolde M, Weigand I, Gätzner S, Manova K et al..  2017.  VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.. Oncogene. 36(1):1-12.

Zloza A, A Palucka K, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA et al..  2017.  Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.. J Immunother Cancer. 5(1):77.

Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S et al..  2016.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.. Genome Biol. 17(1):174.

Becker A, Thakur BKumar, Weiss JMitchell, Kim HSang, Peinado H, Lyden D.  2016.  Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis.. Cancer Cell. 30(6):836-848.

Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D et al..  2016.  Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.. Cancer Immunol Res. 4(11):936-947.

Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA.  2016.  Opportunities and challenges for TCR mimic antibodies in cancer therapy.. Expert Opin Biol Ther. 16(8):979-87.

Guo J, Chakraborty AA, Liu P, Gan W, Zheng X, Inuzuka H, Wang B, Zhang J, Zhang L, Yuan M et al..  2016.  pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner.. Science. 353(6302):929-32.

Lane BR, Bissonnette J, Waldherr T, Ritz-Holland D, Chesla D, Cottingham SL, Alberta S, Liu C, Thompson AB, Graveel C et al..  2015.  Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.. J Mol Diagn. 17(6):695-704.

Das LTanmoy, Wagner CD, Bigatti SM.  2015.  Illness representations of cancer among healthy residents of Kolkata, India.. Asian Pac J Cancer Prev. 16(2):845-52.

Heilmann S, Ratnakumar K, Langdon E, Kansler E, Kim I, Campbell NR, Perry E, McMahon A, Kaufman C, van Rooijen E et al..  2015.  A Quantitative System for Studying Metastasis Using Transparent Zebrafish.. Cancer Res. 75(20):4272-4282.